Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant

Kohei Nagasawa, Y. Tada, S. Koarada, H. Tsukamoto, Takahiko Horiuchi, S. Yoshizawa, K. Murai, A. Ueda, Y. Haruta, A. Ohta

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Although osteonecrosis of femoral head (ONF) is one of the serious complications in systemic lupus erythematosus (SLE) associated with corticosteroid therapy, there has been few trials of prevention of ONF described. We aimed to prevent ONF in steroid-treated SLE patients using anticoagulant, warfarin, conducting a multicenter prospective study. Sixty newly diagnosed SLE patients requiring 40 mg/day or more prednisolone were alternately assigned to either of two groups; a warfarin group and a control one. Warfarin (1-5 mg/day) was started together with the beginning of steroid therapy and continued at least for three months. Patients were observed for the development of silent ONF by magnetic resonance imaging (MRI) and symptomatic ONF by plain radiography for over five years. The warfarin group consisted of 31 patients (62 hips) and the control one 29 patients (58 hips). Silent ONF developed in 13 hips (21%) and 19 hips (33%) in the warfarin group and the control group, respectively (P = 0.13). On the other hand, warfarin tended to prevent symptomatic ONF; only three hips of 62 (4.8%) in the warfarin group and eight hips of 58 (14%) in the control group (P = 0.08) developed silent ONF. It was also found that silent ONF developed, if it did, very early; within three months in 16 of 18 patients (89%). Among risk factors for silent ONF, steroid pulse therapy was most outstanding and it seemed to overcome the effect of warfarin. Taken together, for the time being, anticoagulant therapy, if not significantly sufficient, may be of use for the prevention of steroid-induced ONF in SLE. We consider that this study added to important evidence for the pathogenesis and prevention of ONF.

Original languageEnglish
Pages (from-to)354-357
Number of pages4
JournalLupus
Volume15
Issue number6
DOIs
Publication statusPublished - Jul 17 2006

Fingerprint

Coagulants
Osteonecrosis
Thigh
Systemic Lupus Erythematosus
Steroids
Warfarin
Hip
Anticoagulants
Control Groups
Therapeutics
Prednisolone
Radiography
Multicenter Studies
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. / Nagasawa, Kohei; Tada, Y.; Koarada, S.; Tsukamoto, H.; Horiuchi, Takahiko; Yoshizawa, S.; Murai, K.; Ueda, A.; Haruta, Y.; Ohta, A.

In: Lupus, Vol. 15, No. 6, 17.07.2006, p. 354-357.

Research output: Contribution to journalArticle

Nagasawa, K, Tada, Y, Koarada, S, Tsukamoto, H, Horiuchi, T, Yoshizawa, S, Murai, K, Ueda, A, Haruta, Y & Ohta, A 2006, 'Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant', Lupus, vol. 15, no. 6, pp. 354-357. https://doi.org/10.1191/0961203306lu2311oa
Nagasawa, Kohei ; Tada, Y. ; Koarada, S. ; Tsukamoto, H. ; Horiuchi, Takahiko ; Yoshizawa, S. ; Murai, K. ; Ueda, A. ; Haruta, Y. ; Ohta, A. / Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. In: Lupus. 2006 ; Vol. 15, No. 6. pp. 354-357.
@article{cdf5f8d442b94ef49d342d5e8a28fe9e,
title = "Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant",
abstract = "Although osteonecrosis of femoral head (ONF) is one of the serious complications in systemic lupus erythematosus (SLE) associated with corticosteroid therapy, there has been few trials of prevention of ONF described. We aimed to prevent ONF in steroid-treated SLE patients using anticoagulant, warfarin, conducting a multicenter prospective study. Sixty newly diagnosed SLE patients requiring 40 mg/day or more prednisolone were alternately assigned to either of two groups; a warfarin group and a control one. Warfarin (1-5 mg/day) was started together with the beginning of steroid therapy and continued at least for three months. Patients were observed for the development of silent ONF by magnetic resonance imaging (MRI) and symptomatic ONF by plain radiography for over five years. The warfarin group consisted of 31 patients (62 hips) and the control one 29 patients (58 hips). Silent ONF developed in 13 hips (21{\%}) and 19 hips (33{\%}) in the warfarin group and the control group, respectively (P = 0.13). On the other hand, warfarin tended to prevent symptomatic ONF; only three hips of 62 (4.8{\%}) in the warfarin group and eight hips of 58 (14{\%}) in the control group (P = 0.08) developed silent ONF. It was also found that silent ONF developed, if it did, very early; within three months in 16 of 18 patients (89{\%}). Among risk factors for silent ONF, steroid pulse therapy was most outstanding and it seemed to overcome the effect of warfarin. Taken together, for the time being, anticoagulant therapy, if not significantly sufficient, may be of use for the prevention of steroid-induced ONF in SLE. We consider that this study added to important evidence for the pathogenesis and prevention of ONF.",
author = "Kohei Nagasawa and Y. Tada and S. Koarada and H. Tsukamoto and Takahiko Horiuchi and S. Yoshizawa and K. Murai and A. Ueda and Y. Haruta and A. Ohta",
year = "2006",
month = "7",
day = "17",
doi = "10.1191/0961203306lu2311oa",
language = "English",
volume = "15",
pages = "354--357",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant

AU - Nagasawa, Kohei

AU - Tada, Y.

AU - Koarada, S.

AU - Tsukamoto, H.

AU - Horiuchi, Takahiko

AU - Yoshizawa, S.

AU - Murai, K.

AU - Ueda, A.

AU - Haruta, Y.

AU - Ohta, A.

PY - 2006/7/17

Y1 - 2006/7/17

N2 - Although osteonecrosis of femoral head (ONF) is one of the serious complications in systemic lupus erythematosus (SLE) associated with corticosteroid therapy, there has been few trials of prevention of ONF described. We aimed to prevent ONF in steroid-treated SLE patients using anticoagulant, warfarin, conducting a multicenter prospective study. Sixty newly diagnosed SLE patients requiring 40 mg/day or more prednisolone were alternately assigned to either of two groups; a warfarin group and a control one. Warfarin (1-5 mg/day) was started together with the beginning of steroid therapy and continued at least for three months. Patients were observed for the development of silent ONF by magnetic resonance imaging (MRI) and symptomatic ONF by plain radiography for over five years. The warfarin group consisted of 31 patients (62 hips) and the control one 29 patients (58 hips). Silent ONF developed in 13 hips (21%) and 19 hips (33%) in the warfarin group and the control group, respectively (P = 0.13). On the other hand, warfarin tended to prevent symptomatic ONF; only three hips of 62 (4.8%) in the warfarin group and eight hips of 58 (14%) in the control group (P = 0.08) developed silent ONF. It was also found that silent ONF developed, if it did, very early; within three months in 16 of 18 patients (89%). Among risk factors for silent ONF, steroid pulse therapy was most outstanding and it seemed to overcome the effect of warfarin. Taken together, for the time being, anticoagulant therapy, if not significantly sufficient, may be of use for the prevention of steroid-induced ONF in SLE. We consider that this study added to important evidence for the pathogenesis and prevention of ONF.

AB - Although osteonecrosis of femoral head (ONF) is one of the serious complications in systemic lupus erythematosus (SLE) associated with corticosteroid therapy, there has been few trials of prevention of ONF described. We aimed to prevent ONF in steroid-treated SLE patients using anticoagulant, warfarin, conducting a multicenter prospective study. Sixty newly diagnosed SLE patients requiring 40 mg/day or more prednisolone were alternately assigned to either of two groups; a warfarin group and a control one. Warfarin (1-5 mg/day) was started together with the beginning of steroid therapy and continued at least for three months. Patients were observed for the development of silent ONF by magnetic resonance imaging (MRI) and symptomatic ONF by plain radiography for over five years. The warfarin group consisted of 31 patients (62 hips) and the control one 29 patients (58 hips). Silent ONF developed in 13 hips (21%) and 19 hips (33%) in the warfarin group and the control group, respectively (P = 0.13). On the other hand, warfarin tended to prevent symptomatic ONF; only three hips of 62 (4.8%) in the warfarin group and eight hips of 58 (14%) in the control group (P = 0.08) developed silent ONF. It was also found that silent ONF developed, if it did, very early; within three months in 16 of 18 patients (89%). Among risk factors for silent ONF, steroid pulse therapy was most outstanding and it seemed to overcome the effect of warfarin. Taken together, for the time being, anticoagulant therapy, if not significantly sufficient, may be of use for the prevention of steroid-induced ONF in SLE. We consider that this study added to important evidence for the pathogenesis and prevention of ONF.

UR - http://www.scopus.com/inward/record.url?scp=33745846795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745846795&partnerID=8YFLogxK

U2 - 10.1191/0961203306lu2311oa

DO - 10.1191/0961203306lu2311oa

M3 - Article

C2 - 16830881

AN - SCOPUS:33745846795

VL - 15

SP - 354

EP - 357

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 6

ER -